Recombinant Capital Presents
ALLICENSE 2004
CREATING AND SHARING VALUE THROUGH ALLIANCES
April 6 & 7, 2004
Westin St. Francis Hotel, San Francisco, CA
Program Agenda
All Speakers confirmed
Tuesday, April 6
8:00 – 8:15
Welcoming Remarks & Conference Overview: Creating & Sharing Value Through Alliances
· Mark G. Edwards, Managing Director, Recombinant Capital
8:15 – 9:00
Keynote Presentation – Drug Discovery in the 21st Century: The Amgen Approach to R&D
· Dr. Roger M. Perlmutter, Executive Vice President, Research & Development, Amgen
9:00 – 10:30
Session 1: Strategies for the Winning Product Portfolio – A Panel Discussion
· Session Chair: Kenneth Weg, Chairman, Clearview Projects
· Prof. Jan Lundberg, Executive Vice President, Discovery Research, AstraZeneca
· Myrtle S. Potter, President, Commercial Operations, Genentech
· Rick E. Winningham, Chief Executive Officer, Theravance
Morning Break 10:30 – 11:00
11:00 – 12:30
Session 2: The Shape of Things to Come – Where Will Alliances Take the Pharma Industry Over the Next Decade?
· Session Chair: Barbara Yanni, Chief Licensing Officer, Merck & Co
· Lisa Ricciardi, Vice President Licensing & Development, Pfizer
· David E. Thompson, Vice President, Strategy & Business Development, Eli Lilly
12:30 – 2:00
Luncheon hosted by:
2:00 – 3:00
Session 3: Anatomy of a Major Alliance
· Kenneth A. Berlin, Vice President, Licensing & New Business Development, Ortho Biotech
· Anna Protopapas, Vice President, Corporate and Business Development, Millennium Pharmaceuticals
Afternoon Break 3:00 - 3:30
3:30 – 5:30
Session 4: Business Strategy & Alliances: A Roundtable Discussion
· Session Chair: Jack M. Anthony, Senior Vice President, Business and Commercial Development, Tularik
· Tamar Howson, Senior Vice President, Corporate and Business Development, Bristol-Myers Squibb
· Prof. Hans Hultberg, Global Head of Discovery Alliances, AstraZeneca
· Joseph McCracken, Vice President, Business & Commercial Development, Genentech
· Lisa Ricciardi, Vice President Licensing & Development, Pfizer
· David E. Thompson, Vice President, Strategy & Business Development, Eli Lilly
· Barbara Yanni, Chief Licensing Officer, Merck & Co
ALLICENSE 2004 Breakthrough Alliance Awards Dinner
Westin St. Francis Hotel
6:00 - 7:00 Cocktail Reception, The Italian Room Foyer
7:00 - 9:30 Dinner and Awards Ceremony, The Colonial Room
(All registered attendees are invited to attend the Reception and Awards Dinner)
....................................................................
Wednesday, April 7
8:00 – 8:30
Trends in Pharma/Biotech Alliances – Lessons from 2003
· Mark G. Edwards, Managing Director, Recombinant Capital
8:30 – 9:15
Keynote Presentation – Harnessing Emerging Technology to Boost Innovation
· Prof. Jan Lundberg, Executive Vice President, Discovery Research, AstraZeneca
9:15 – 9:45
Building a Company, Choosing a Partner
· Dr. David R. Guyer, Chief Executive Officer, Eyetech Pharmaceuticals
Morning Break 9:45 – 10:15
10:15 – 12:00
Session 5: Setting the Alliance Agenda for Pharma and Biotech
· Session Chair: Frances Heller, Head, Strategic Alliances, Novartis
· James J. Egan, Senior Vice President, Business & Corporate Development, Idenix Pharmaceuticals
· Dr. Mark L. Lee, Senior Vice President, Business Development Pharma and Head, Worldwide Licensing, Wyeth
· R. Christopher Seaton, Senior Vice President, Global Licensing, Bayer Corporation
12:00 – 1:30
Luncheon hosted by:
1:30 – 3:30
Session 6: Key Negotiation Issues: A Roundtable Discussion
· Session Chair: Robert Jones, Managing Partner, Cooley Godward
· Brad W. Crawford, Director, Licensing, Amgen
· Frances Heller, Head, Strategic Alliances, Novartis
· Dr. Mark L. Lee, Senior Vice President, Business Development Pharma and Head, Worldwide Licensing, Wyeth
· Adelene Q. Perkins, Chief Business Officer, Infinity Pharmaceuticals
Afternoon Break 3:30 – 4:00
4:00 – 5:30
Session 7: Specialty Pharma: The Wave of the Future or a Tsunami Heading to Shore?
· Session Chair: Dr. Ronald A. Pepin, Senior Vice President, Business Development, Medarex
· Dr. Les Browne, Chief Operating Officer, Iconix Pharmaceuticals
· Chris Ehrlich, Venture Partner, InterWest Partners
· Michael G. McCully, Director and Senior Analyst, Recombinant Capital
Closing Reception
5:30 - 6:30PM
|